Literature DB >> 27148623

Rational Design of Calpain Inhibitors Based on Calpastatin Peptidomimetics.

Kristin E Low1, Spencer Ler2, Kevin J Chen1, Robert L Campbell1, Jennifer L Hickey3, Joanne Tan2, Conor C G Scully2, Peter L Davies1, Andrei K Yudin2, Serge Zaretsky2.   

Abstract

Our previously reported structures of calpain bound to its endogenous inhibitor calpastatin have motivated the use of aziridine aldehyde-mediated peptide macrocyclization toward the design of cyclic peptides and peptidomimetics as calpain inhibitors. Inspired by nature's hint that a β-turn loop within calpastatin forms a broad interaction around calpain's active site cysteine, we have constructed and tested a library of 45 peptidic compounds based on this loop sequence. Four molecules have shown reproducibly low micromolar inhibition of calpain-2. Further systematic sequence changes led to the development of probes that displayed increased potency and specificity of inhibition against calpain over other cysteine proteases. Calculated Ki values were in the low micromolar range, rivaling other peptidomimetic calpain inhibitors and presenting an improved selectivity profile against other therapeutically relevant proteases. Competitive and mixed inhibition against calpain-2 was observed, and an allosteric inhibition site on the enzyme was identified for a noncompetitive inhibitor.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27148623     DOI: 10.1021/acs.jmedchem.6b00267

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  8 in total

Review 1.  Calpain research for drug discovery: challenges and potential.

Authors:  Yasuko Ono; Takaomi C Saido; Hiroyuki Sorimachi
Journal:  Nat Rev Drug Discov       Date:  2016-11-11       Impact factor: 84.694

2.  Solid-phase synthesis, cyclization, and site-specific functionalization of aziridine-containing tetrapeptides.

Authors:  Benjamin K W Chung; Christopher J White; Andrei K Yudin
Journal:  Nat Protoc       Date:  2017-05-24       Impact factor: 13.491

Review 3.  Calpains as mechanistic drivers and therapeutic targets for ocular disease.

Authors:  Jennifer T Vu; Elena Wang; Jolan Wu; Young Joo Sun; Gabriel Velez; Alexander G Bassuk; Soo Hyeon Lee; Vinit B Mahajan
Journal:  Trends Mol Med       Date:  2022-05-29       Impact factor: 15.272

4.  Mitigating the Metabolic Liability of Carbonyl Reduction: Novel Calpain Inhibitors with P1' Extension.

Authors:  Andreas Kling; Katja Jantos; Helmut Mack; Wilfried Hornberger; Gisela Backfisch; Yanbin Lao; Marjoleen Nijsen; Beatrice Rendenbach-Mueller; Achim Moeller
Journal:  ACS Med Chem Lett       Date:  2018-02-04       Impact factor: 4.345

5.  The C2 domain of calpain 5 contributes to enzyme activation and membrane localization.

Authors:  Vimala Bondada; Jozsef Gal; Charles Mashburn; David W Rodgers; Katherine E Larochelle; Dorothy E Croall; James W Geddes
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2021-03-31       Impact factor: 5.011

Review 6.  Why calpain inhibitors are interesting leading compounds to search for new therapeutic options to treat leishmaniasis?

Authors:  Vitor Ennes-Vidal; Rubem Figueiredo Sadock Menna-Barreto; Marta Helena Branquinha; André Luis Souza Dos Santos; Claudia Masini D'Avila-Levy
Journal:  Parasitology       Date:  2016-11-21       Impact factor: 3.234

7.  Diversity of Secondary Structure in Catalytic Peptides with β-Turn-Biased Sequences.

Authors:  Anthony J Metrano; Nadia C Abascal; Brandon Q Mercado; Eric K Paulson; Anna E Hurtley; Scott J Miller
Journal:  J Am Chem Soc       Date:  2016-12-28       Impact factor: 15.419

8.  Natalenamides A⁻C, Cyclic Tripeptides from the Termite-Associated Actinomadura sp. RB99.

Authors:  Seoung Rak Lee; Dahae Lee; Jae Sik Yu; René Benndorf; Sullim Lee; Dong-Soo Lee; Jungmoo Huh; Z Wilhelm de Beer; Yong Ho Kim; Christine Beemelmanns; Ki Sung Kang; Ki Hyun Kim
Journal:  Molecules       Date:  2018-11-16       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.